Skip to main content
. Author manuscript; available in PMC: 2011 Jul 31.
Published in final edited form as: AIDS. 2010 Jul 31;24(12):1877–1886. doi: 10.1097/QAD.0b013e32833b1b26

Table-3.

Non-AIDS events

Adjusted Analysis* AIC
Predictors HR p p for trend 95%CI
Latest CD4 per log2 rise(i.e. doubling) 0.73 <0.001 0.62–.86 3000.46
Latest CD4>500 ref
350–500 0.79 0.246 0.001 0.53–1.17 2997.93
200–350 1.20 0.371 0.80–1.79
50–200 2.11 0.003 1.29–3.45
<50 4.81 0.001 1.89–12.25
Latest CD4 per 100 cells rise 0.93 0.073 0.86–1.00 3009.88
Baseline CD4 per 100cell rise 0.97 0.573 0.87–1.07 3012.93
Latest CD% >25 ref
CD4% 14–25 1.26 0.162 0.161 0.90–1.76 3013.33
CD% <14 1.49 0.072 0.96–2.32
Nadir CD4 count per 100 rise 0.93 0.286 0.81–1.06 3011.62
CD4 slope over 3 consecutive visits
>0 ref
<=0 0.95 0.745 0.413 0.72–1.25 3008.02
CD4 slope over 7 consecutive visits
±10 (i.e. Plateau) ref
<-10 cells/mm3 per month 1.25 0.500 0.345 0.64–2.43 3016.04
>10 cells/mm3 per month 1.08 0.784 0.62–1.88
Time spent (per year) with CD4<200 1.14 0.015 1.02–1.27 3007.72
Time spent (per year) with CD4<100 1.30 0.002 1.10–1.53 3005.93
Time spent (per year) with CD4<50 1.80 0.030 1.05–3.08 3010.03
Effect of addition of significant CD4+ metrics**
Model1
Time spent (per year) with CD4<200 1.04 0.453 0.92–1.18
Model2
Time spent (per year) with CD4<100 1.16 0.129 0.95–1.41
Model3
Time spent (per year) with CD4<50 1.29 0.416 0.69–2.38

CD4= CD4+ T-cells/mm3, unless otherwise stated.

*

Stratified by trial and adjusted for gender, age, prior aids at baseline, ART duration at baseline, current ART class, region, race, HIV RNA (as time-updated variable). AIC= Akaike information criteria.

**

Each model is the adjusted model for log2 rise in CD4+ (highlighted above) after addition of each of the significant CD4+ metrics above. Log2 rise in CD4+ remained statistically significant in all models (1–3) at p<0.004.